Resolution Therapeutics Reports Positive Interim Phase I/II Data for RTX001
Six-month interim data showed a 42% relative risk reduction in death, liver transplant or hepatic de…
Related stories
FGC Reports System Intrusion and Personal Data Leak
Brazil’s Fundo Garantidor de Créditos (FGC) reports an intrusion into its system and a leak of personal data.
M impact | EQUITY | Nov 05, 2026, 03:42 PM UTC
Evergy raises 2026 profit forecast after Q3 beat; shares climb 2.6%
Evergy lifted its 2026 profit forecast after beating expectations in the third quarter. Shares rose 2.6%.
M impact | EQUITY | Nov 05, 2026, 03:42 PM UTC
Cogent Communications Reports Third-Quarter Revenue of $231.2 Million
Cogent Communications' third-quarter service revenue fell 4.4% year over year, while its net loss narrowed. Revenue was pressured by cancellations of low-margin and non-core custom
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Weis Markets Reports Third-Quarter 2026 Revenue of $1.28 Billion, EPS of $0.90
Weis Markets said third-quarter revenue and earnings increased year over year. Higher fuel sales primarily drove sales growth, while higher gross profit increased gross margin; low
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Sunoco Reports Third-Quarter Revenue of $18.03 Billion, EPS of $2.07
Sunoco said revenue and earnings increased year over year, primarily reflecting higher segment adjusted EBITDA in fuel distribution, terminals and refining. The largest gains were
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Lemonade Reports Third-Quarter Revenue of $336.1M, EPS Loss of $0.56
Revenue rose 73% year over year, while the net loss widened 17%. Growth reflected higher net earned premium from increased gross written premium and a lower reinsurance cession rat
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC